Merck-Eisai's endometrial cancer therapy combo fails first-line treatment trial

Merck (MRK.N) said on Friday a combination therapy being developed with partner Eisai (4523.T) failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining.